Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus?
Teodoro J. Oscanoa, Román Romero‐Ortuño, Alfonso Carvajal, et al.
International Journal of Antimicrobial Agents (2020) Vol. 56, Iss. 3, pp. 106078-106078
Open Access | Times Cited: 52

Showing 1-25 of 52 citing articles:

Identification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing Screen
Maria Kuzikov, Elisa Costanzi, Jeanette Reinshagen, et al.
ACS Pharmacology & Translational Science (2021) Vol. 4, Iss. 3, pp. 1096-1110
Open Access | Times Cited: 138
Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants
Lucy Catteau, Nicolás Dauby, Marion Montourcy, et al.
International Journal of Antimicrobial Agents (2020) Vol. 56, Iss. 4, pp. 106144-106144
Open Access | Times Cited: 121
Enhancing autophagy in Alzheimer's disease through drug repositioning
Mehdi Eshraghi, Mazaher Ahmadi, Saeid Afshar, et al.
Pharmacology & Therapeutics (2022) Vol. 237, pp. 108171-108171
Closed Access | Times Cited: 63
A multi-targeting drug design strategy for identifying potent anti-SARS-CoV-2 inhibitors
Pengxuan Ren, Weijuan Shang, Wanchao Yin, et al.
Acta Pharmacologica Sinica (2021) Vol. 43, Iss. 2, pp. 483-493
Open Access | Times Cited: 60
Nano-Biomimetic Drug Delivery Vehicles: Potential Approaches for COVID-19 Treatment
Bwalya A. Witika, Pedzisai A. Makoni, Larry L Mweetwa, et al.
Molecules (2020) Vol. 25, Iss. 24, pp. 5952-5952
Open Access | Times Cited: 45
Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19
Pravindra Kumar, Ashok Kumar Sah, Greesham Tripathi, et al.
Molecular and Cellular Biochemistry (2020) Vol. 476, Iss. 2, pp. 553-574
Open Access | Times Cited: 40
Lipophilicity, Pharmacokinetic Properties, and Molecular Docking Study on SARS-CoV-2 Target for Betulin Triazole Derivatives with Attached 1,4-Quinone
Monika Kadela-Tomanek, Maria Jastrzębska, Krzysztof Marciniec, et al.
Pharmaceutics (2021) Vol. 13, Iss. 6, pp. 781-781
Open Access | Times Cited: 39
Nano-engineered tools in the diagnosis, therapeutics, prevention, and mitigation of SARS-CoV-2
Siya Kamat, Madhuree Kumari, Chelliah Jayabaskaran
Journal of Controlled Release (2021) Vol. 338, pp. 813-836
Open Access | Times Cited: 39
Chloroquine and Hydroxychloroquine: Efficacy in the Treatment of the COVID-19
Tzu‐Chuan Ho, Yung-Hsuan Wang, Yi‐Ling Chen, et al.
Pathogens (2021) Vol. 10, Iss. 2, pp. 217-217
Open Access | Times Cited: 30
Autophagy, Unfolded Protein Response, and Neuropilin-1 Cross-Talk in SARS-CoV-2 Infection: What Can Be Learned from Other Coronaviruses
Morvarid Siri, Sanaz Dastghaib, Mozhdeh Zamani, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 11, pp. 5992-5992
Open Access | Times Cited: 29
Therapeutic Potential of Exploiting Autophagy Cascade Against Coronavirus Infection
Subhajit Maity, Abhik Saha
Frontiers in Microbiology (2021) Vol. 12
Open Access | Times Cited: 28
Roles of host mitochondria in the development of COVID-19 pathology: Could mitochondria be a potential therapeutic target?
Kavya Srinivasan, Ashutosh Pandey, Ashlena Livingston, et al.
Molecular Biomedicine (2021) Vol. 2, Iss. 1
Open Access | Times Cited: 27
Efficacy and safety of chloroquine and hydroxychloroquine for treatment of COVID-19 patients-a systematic review and meta-analysis of randomized controlled trials.
Paul Eze, Kenechukwu Mezue, Chidozie Nduka, et al.
PubMed (2021) Vol. 11, Iss. 1, pp. 93-107
Closed Access | Times Cited: 23
Pharmacokinetic Basis of the Hydroxychloroquine Response in COVID-19: Implications for Therapy and Prevention
Mohammad Tarek, Andrea Savarino
European Journal of Drug Metabolism and Pharmacokinetics (2020) Vol. 45, Iss. 6, pp. 715-723
Open Access | Times Cited: 21
Diclofenac, ibuprofen, and paracetamol biodegradation: overconsumed non-steroidal anti-inflammatories drugs at COVID-19 pandemic
Beatriz L. Ferreira, Dionisia P. Ferreira, Swanny F. Borges, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 6
Identification of lead compounds from large natural product library targeting 3C-like protease of SARS-CoV-2 using E-pharmacophore modelling, QSAR and molecular dynamics simulation
Olusola Olalekan Elekofehinti, Opeyemi Iwaloye, Olorunfemi R. Molehin, et al.
In Silico Pharmacology (2021) Vol. 9, Iss. 1
Open Access | Times Cited: 14
Design, synthesis and antiviral evaluation of novel conjugates of the 1,7,7‐trimethylbicyclo[2.2.1]heptane scaffold and saturated N‐heterocycles via 1,2,3‐triazole linker
А. С. Соколова, Оlga I. Yarovaya, Оleg I. Аrtyushin, et al.
Archiv der Pharmazie (2023) Vol. 357, Iss. 3
Closed Access | Times Cited: 5
Hydroxychloroquine: Pharmacokinetics and Toxicity
P. Brouqui, Éric Chabrière, Didier Raoult
Journal of Clinical Pharmacy and Therapeutics (2024) Vol. 2024, pp. 1-12
Open Access | Times Cited: 1
Biomimetic properties and estimated in vivo distribution of chloroquine and hydroxy-chloroquine enantiomers
Klára Valkó, Tong Zhang
ADMET & DMPK (2021)
Open Access | Times Cited: 12
Diagnosis and Critique of Drugs Used in Treating Coronavirus Disease in 2019 in Nigeria: A Review
Tajudeen Olusegun Rasheed, Wael Mohamed Noaman Higazy, Bilawu Yisa Abiodun
Pharmaceutical and Biomedical Research (2023) Vol. 9, Iss. 4, pp. 259-266
Open Access | Times Cited: 4
Blood matters: the hematological signatures of Coronavirus infection
Ayelén Toro, Ana Paula Arévalo, Marianoel Pereira‐Gomez, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 11
Open Access | Times Cited: 1
Hydroxychloroquine lung pharmacokinetics in critically ill patients with COVID-19
Stéphanie Ruiz, Didier Concordet, Thomas Lanot, et al.
International Journal of Antimicrobial Agents (2020) Vol. 57, Iss. 2, pp. 106247-106247
Open Access | Times Cited: 10
Pharmacoepidemiology, Machine Learning, and COVID-19: An Intent-to-Treat Analysis of Hydroxychloroquine, With or Without Azithromycin, and COVID-19 Outcomes Among Hospitalized US Veterans
Hanna Gerlovin, Daniel Posner, Yuk‐Lam Ho, et al.
American Journal of Epidemiology (2021) Vol. 190, Iss. 11, pp. 2405-2419
Open Access | Times Cited: 8
Effects of chloroquine or hydroxychloroquine treatment on non‐SARS‐CoV2 viral infections: A systematic review of clinical studies
Xizhong Cui, Junfeng Sun, S. Minkove, et al.
Reviews in Medical Virology (2021) Vol. 31, Iss. 6
Open Access | Times Cited: 7
Molecular Docking of Quinine Derivative as Inhibitor in Sars-Cov-2
Destria Roza, Rini Selly, Rudi Munsirwan, et al.
Journal of Physics Conference Series (2021) Vol. 1819, Iss. 1, pp. 012053-012053
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top